Previous Article | Next Article 
Infection and Immunity, August 2000, p. 4585-4592, Vol. 68, No. 8
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Role of Pulmonary Alveolar Macrophages in Defense
of the Lung against Pseudomonas aeruginosa
Dorothy O. Y.
Cheung,1
Keith
Halsey,2 and
David P.
Speert1,2,*
Department of Pathology and Laboratory
Medicine1 and Division of Infectious and
Immunological Diseases, Department of
Pediatrics,2 University of British Columbia,
Vancouver, British Columbia, Canada
Received 1 March 2000/Returned for modification 28 March
2000/Accepted 17 May 2000
 |
ABSTRACT |
Alveolar macrophages (AM) provide one of the first lines of defense
against microbial invasion in the lower airways. The role of AM in the
clearance of Pseudomonas aeruginosa in mice after intrapulmonary challenge was evaluated. AM were depleted by intranasal administration of liposome-encapsulated dichloromethylene
diphosphonate. At 24 h following the instillation of liposomes, a
sublethal dose of P. aeruginosa was inoculated
intranasally. Spleen, liver, and lung tissue was then evaluated for
viable bacteria and for histopathology. AM depletion of 78 to 88% did
not affect the survival rate of infected mice or clearance of P. aeruginosa from the spleen, liver, or lung, compared to the
control group, but the mice's susceptibility to Klebsiella
pneumoniae was greatly enhanced. The recruitment of neutrophils
to the lung was also not affected. Freshly explanted AM were not
competent to phagocytose unopsonized P. aeruginosa but were
able to phagocytose zymosan particles. Further studies were conducted
to assess the in situ phagocytic activities of AM. Three hours after
the intranasal instillation of P. aeruginosa or other
particles, bronchoalveolar lavage was performed. AM phagocytosis of
zymosan particles and latex beads exceeded that of P. aeruginosa. Neutrophils were recruited to the lung in response to
a high-dose bacterial challenge. These results suggest that AM do not
play an important role in defense of the lung against P. aeruginosa.
 |
INTRODUCTION |
Pseudomonas aeruginosa is
a gram-negative, opportunistic pathogen that causes chronic infections
in cystic fibrosis (CF) patients, immunocompromised individuals, and
burn patients. Infection of the lung is the leading cause of morbidity
and mortality in CF patients. Once acquired, this bacterium is
difficult to treat and is rarely eradicated. Most strains of P. aeruginosa show substantial degrees of resistance to a wide
variety of antimicrobial agents (12, 21).
Alveolar macrophages (AM), located at the interphase between air and
lung tissue, provide the first line of phagocytic defense against
microbial invasion in the lower respiratory tract. Besides their
phagocytic and microbicidal functions, AM also secrete numerous chemical mediators upon stimulation, thereby playing a role in regulating inflammatory reactions in the lung (14). The role of AM in defending the lung against various pathogens and in regulating inflammatory reactions has been assessed in studies in which AM were
depleted. In rodent models, AM can be depleted to 5 to 30% of normal
numbers by liposome-encapsulated dichloromethylene diphosphonate (LDMDP) delivered to the pulmonary tract (2, 4, 13, 15-17). The usual fate of liposomes is ingestion and digestion by macrophages. Due to its strong hydrophilic properties, DMDP is not able to escape
from the cell when released intracellularly. Therefore, macrophages are
selectively depleted without damaging other tissues or cells
(27).
AM are the primary phagocytic cells in the uninflamed lower airways.
Phagocytosis is categorized into opsonic and nonopsonic mechanisms.
Opsonic phagocytosis is mediated by Fc and complement receptors.
However, human and mouse AM show minimal expression of receptors for
C3b/iC3b (CR1/CR3/CR4). The receptors for immunoglobulin G, Fc
receptors, are expressed in human AM but negligibly in mouse AM
(3, 24). Furthermore, the concentrations of complement and
immunoglobulin in the lower airway are minimal; therefore, it is likely
that AM utilize nonopsonic, instead of Fc or complement receptor-mediated, phagocytosis to eliminate pathogens such as P. aeruginosa from the lung. We and others have evaluated the in
vitro response of macrophages to challenge with P. aeruginosa and other particles (1, 3, 8, 22, 29).
The main objective of this study was to further elucidate the in vivo
role of AM in defense of the lung against P. aeruginosa challenge. AM were depleted by the intranasal (i.n.) instillation of
LDMDP in mice. AM-depleted mice received a sublethal dose of P. aeruginosa or Klebsiella pneumoniae (as a positive
control) by i.n. inoculation. The effects of AM depletion on bacterial clearance in spleen, liver, and lung and on polymorphonuclear leukocyte
(PMN) recruitment to the lung were assessed. Secondly, the in vitro
phagocytosis of unopsonized P. aeruginosa, zymosan, and
latex beads by freshly explanted murine AM was compared to that by
peritoneal macrophages (PM). Finally, assessment of the in situ
phagocytic activities of AM was performed by challenging mice i.n. with
unopsonized P. aeruginosa, zymosan particles, or latex beads
and subsequently obtaining bronchoalveolar lavage (BAL) fluid to
evaluate BAL cell numbers and the number of ingested particles per cell
in the BAL-derived population.
 |
MATERIALS AND METHODS |
Bacterial strains and culture conditions.
P.
aeruginosa strain P1 is a nonmucoid, lipopolysaccharide
(LPS)-rough derivative of a mucoid isolate from a patient with CF.
Strain c2908c was the initial colonizing isolate obtained from a CF
patient. Strain PAK (LPS smooth) was obtained from W. Paranchych
(Edmonton, Alberta, Canada), PA01 (LPS smooth) was from B. Holloway
(Victoria, Australia), and FRD1 was from R. E. W. Hancock
(Vancouver, British Columbia, Canada). K. pneumoniae (ATCC
43816) was purchased from the American Type Culture Collection (Manassas, Va.). Bacteria were kept frozen at
70°C in
Mueller-Hinton broth with 8.0% dimethyl sulfoxide and grown fresh for
each experiment. They were grown with shaking overnight in L broth at
37°C.
Animals.
Specific-pathogen-free (SPF) male CD-1 mice
weighing 35 to 37 g were obtained from Charles River Laboratories
Canada (St. Constant, Quebec, Canada), and SPF female BALB/c mice
weighing 20 to 22 g were obtained from the University of British
Columbia Animal Care Centre, Vancouver, British Columbia, Canada. All
mice were housed under Canadian Council on Animal Care-approved SPF conditions in the animal care facility at the British Columbia Research
Institute for Children's and Women's Health, Vancouver, British
Columbia, Canada. The animal procedures were approved by the University
of British Columbia Committee on Animal Care, Vancouver, British
Columbia, Canada (animal protocol no. A97-0197).
Reagents.
Phagocytosis medium was prepared as described
previously (1). Gel-Hanks' balanced salt solution (gHBSS)
contained 1× HBSS without sodium bicarbonate and phenol red (Gibco
BRL, Grand Island, N.Y.) and 1% gelatin (Gibco BRL).
Preparation of LPBS and LDMDP.
Liposomes were prepared as
previously described (28). Briefly, 86 mg of egg
phosphatidylcholine (Sigma Canada Ltd., Oakville, Ontario, Canada) and
8 mg of cholesterol (Sigma Canada Ltd.) were dissolved in 10 ml of
chloroform in a 500-ml round-bottom flask. The chloroform was
evaporated by rotation under vacuum, and a thin phospholipid film was
formed around the flask. At room temperature, the lipid was dispersed
in 10 ml of phosphate-buffered saline (LPBS) or 0.6 M DMDP (2.5 g in 10 ml of PBS). DMDP was generously provided by Boehringer Mannheim GmbH
(Mannheim, Germany). The suspension was kept at room temperature for
2 h under nitrogen gas and then sonicated for 3 min in a Bransonic
12 water bath sonicator (Bransonic Equipment Co., Shelton, Conn.) and
kept overnight at 4°C. LPBS and LDMDP were centrifuged and washed
three times with sterile PBS at 10,000 × g for 15 min
at 4.0°C to remove free DMDP. The final pellet was resuspended in 4 ml of sterile PBS and used immediately or stored at 4°C under
nitrogen gas. The liposomes were used within 7 days of preparation.
i.n. instillation of liposomes.
Mice were anesthetized using
a dose of 35 mg of ketamine hydrochloride (MTC Pharmaceuticals,
Cambridge, Ontario, Canada)/kg of body weight administered
intraperitoneally. They were inoculated with 2-µl aliquots of LPBS or
LDMDP repeatedly via the external nares for a total volume of 50 µl
(25). The entire procedure required 15 to 20 min per mouse. To assess
the efficiency of LDMDP in depleting AM, BALs were performed on mice
before i.n. challenge with bacteria. The number of AM in BAL fluid from
LDMDP-treated mice was then compared to those from the control mice
exposed to LPBS. For histologic examination, sections of the lung were
excised and fixed in 10% buffered, neutral Formalin (BDH Inc.,
Toronto, Ontario, Canada), processed in a Fisher histomatic 266 tissue
processor, and embedded in paraffin wax blocks. Sections were cut into
2-µm sections and stained with hematoxylin and eosin.
i.n. administration of P. aeruginosa, K. pneumoniae, latex beads, and zymosan.
LPBS and LDMDP were
delivered 24 h prior to bacterial infections. An aliquot of the
overnight culture of P. aeruginosa was harvested by
centrifugation at 13,000 × g for 30 s and
resuspended in the same volume of gHBSS. K. pneumoniae was
grown overnight to late log phase and then harvested by centrifugation
and washed twice with gHBSS for 10 min at 2,075 × g at
room temperature. The bacteria were then diluted with gHBSS to the
desired dose (in CFU per milliliter). The zymosan particles were
prepared as previously described (21). Anesthetized mice
were repeatedly inoculated with 2-µl aliquots of the bacterial
culture dose (106 to 1010 CFU/ml), latex beads
(3 µm), or zymosan; the particles were applied to the external nares
in a total volume of 20 µl (25). The K. pneumoniae dose (100 CFU/mouse) was administered as described above in a total volume of 40 µl. The bacteria were kept on ice prior
to challenge. The entire procedure required 15 to 20 min per mouse.
Serial 1:10 dilutions of the infection inoculum were made in gHBSS,
spread on Trypticase soy agar plates (Becton Dickinson, Cockeysville,
Md.), and incubated for 18 h at 37°C. The inoculation dose was
then evaluated from the viable bacterial CFU.
BAL.
BAL was performed according to procedures described
previously (8). The total BAL cell count, excluding
erythrocytes, was determined with the aid of a hemocytometer (American
Optical, Buffalo, N.Y.) and trypan blue dye exclusion. The differential counts of AM and PMNs were performed on cytocentrifuged preparations using a Cytospin 2 (Shandon Southern Instruments, Sewickley, Pa.) and
stained with Diff-Quik (EM Industries Inc., Gibbstown, N.J.).
Analysis of spleen, liver, and lung bacterial CFU and
histopathology.
Mice were anesthetized with sodium pentobarbital
and killed by cervical dislocation at sequential time points, including
3 h after the i.n. bacterial challenge. Their spleens, livers
(gallbladder removed), and lungs were excised and weighed aseptically.
A section from each tissue was fixed in 10% buffered, neutral Formalin
for histopathology, and the remainder was homogenized for up to 30 s in sterile 10-ml glass tubes with Teflon pestles (Glas-col, Terre
Haute, Ind.). Serial 1:10 dilutions of the homogenates were spread on
Trypticase soy agar plates and incubated for 18 h at 37°C.
Viable bacterial CFU counts were then analyzed. The data are expressed
as the means ± standard errors of the means (SEM) CFU
(log10) per gram of tissue. For histologic examination, the fixed tissue sections were processed, sectioned, and stained with hematoxylin and eosin.
Preparation of murine resident PM.
Resident PM were obtained
from the peritoneal cavities of 6- to 8-week-old SPF female BALB/c mice
as previously described (22). Explanted macrophages were
kept in complete medium. The number of viable cells was determined by
trypan blue exclusion.
In vitro effects of LPBS, LDMDP, and DMDP on murine AM and
PM.
AM and PM were plated at 105 cells per acid-washed
glass coverslip in Falcon 3047 24-well plastic tissue culture trays
(Becton Dickinson, Lincoln Park, N.J.). After 30 min of incubation at 37°C in 5% CO2, 400 µl of complete medium was added to
the wells. After the addition of 5, 10, and 15 µl of either LPBS,
LDMDP, or DMDP, macrophages were incubated at 37°C in 5%
CO2 for 24, 48, and 72 h. At timed intervals,
macrophages were washed twice with PBS, fixed with methanol, stained
with Giemsa stain (BDH Inc.), and mounted on microscope slides with
Entellan mounting medium (Merck, Darmstadt, Germany). The morphology of
untreated and treated AM and PM was assessed microscopically.
Macrophages with intact cytoplasm and nuclei were considered healthy,
while those with no cytoplasm or shriveled cytoplasm and nuclei were considered unhealthy. At least 60 macrophages per coverslip were scored. Each sample was assayed in duplicate, and the experiments were
performed two or three times with different macrophage preparations. Data were expressed as means ± SEM.
In vitro phagocytosis assays.
Phagocytosis assays were
performed as described previously (1) with two
modifications. (i) Two hours after adherence to the coverslips, or 24, 48 and 72 h after incubation with 15 µl of LPBS, LDMDP, and
DMDP, macrophages were washed with PBS twice to remove nonadherent
cells. (ii) D-Glucose (10 mM) was added at the same time as
the bacteria (approximately 107 CFU of unopsonized strain
P1 that were shaken overnight). PM were incubated for 60 min with the
P1 culture. At least 60 macrophages per coverslip were scored
microscopically. The experiments were repeated two or three times with
each sample in duplicate. Data were expressed as means ± SEM.
In vitro effects of LPBS, LDMDP, and DMDP on epithelial cell line
A549.
Epithelial cell line A549, maintained in F12K (Gibco
BRL)-10% fetal calf serum (FCS) (Cansera, Rexdale, Ontario, Canada)
was treated with 1× trypsin-EDTA (Gibco BRL) for 15 min. The cell suspension was centrifuged at 454 × g for 10 min at
4.0°C, and resuspended in F12K-10% FCS. Viable cell counts were
determined with a hemocytometer by trypan blue exclusion. Then
105 cells (in approximately 100 µl) were plated on
acid-washed glass coverslips in 24-well plastic tissue culture trays.
After 30 min of incubation at 37°C in 5% CO2, 400 µl
of F12K-10% FCS was added to the wells. After the addition of 15 µl
of LPBS, LDMDP, or DMDP (600, 50, 5, and 0.5 mM), A549 cells were
incubated at 37°C in 5% CO2 for 24 and 48 h. At
timed intervals, cells were washed twice with PBS, fixed with methanol,
stained with Giemsa, and mounted on microscope slides. The morphology
of untreated and treated epithelial cells was assessed microscopically.
In situ phagocytosis assays.
Anesthetized mice were
challenged i.n. with 20 µl of P. aeruginosa (FRD1, P1,
PAK, PA01, or c2908c), latex beads, or zymosan as described above.
Three hours after instillation, BAL was performed. BAL-derived cells
were centrifuged at 395 × g for 15 min at 4°C, resuspended, and treated with ice-cold lysozyme to lyse uningested bacteria, as previously described (22). The BAL suspension
was centrifuged again and resuspended in 1 ml of PBS. The differential counts of AM and PMNs were performed on Diff-Quik-stained
cytocentrifuge preparations of BAL cells. One hundred cells were
counted, and the results were expressed as percentages of the total.
Data were expressed as means ± SEM.
 |
RESULTS |
In vitro effects of LPBS, LDMDP, and DMDP on the morphology and
phagocytic capacity of murine PM.
Figure
1 shows that the majority (94 to 99%) of
untreated (control) or LPBS-treated PM appeared to be healthy after
48 h. The effects of LDMDP on PM were evident and dose dependent
at 48 h (Fig. 1B). Incubation for 48 h with LDMDP (5, 10, and
15 µl) resulted in a substantial percentage (32, 53, and 71%,
respectively) of PM with shriveled cytoplasm and nuclei compared to the
untreated (1%) and LPBS-treated (0 to 3%) macrophages. As the dose of
LDMDP increased, the percentage of unhealthy-looking macrophages
increased. At 24 h (Fig. 1A) and 48 h (Fig. 1B), all
macrophages incubated with free DMDP appeared to be unhealthy, with no
visible cytoplasm.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 1.
Effects of LPBS, LDMDP, and DMDP on murine PM in vitro.
PM, plated on coverslips, were incubated with 15 µl of LPBS, LDMDP,
or DMDP (0.6 M stock) for 24 h (A) or 48 h (B). Controls
received no treatment. At timed intervals, the morphology of
Giemsa-stained PM was assessed microscopically. The percentages of
healthy macrophages ( ) and unhealthy macrophages ( ) were
compared. One hundred macrophages per coverslip were scored. The
experiments were repeated twice, with each sample in duplicate. Results
are expressed as means plus SEM.
|
|
Table
1 shows that substantially fewer
bacteria were ingested by PM subjected to LDMDP than by control and
LPBS-treated PM.
The percentage of LDMDP-treated PM that ingested
P. aeruginosa was lower than those of untreated and
LPBS-treated PM.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
In vitro phagocytosis of unopsonized P. aeruginosa by murine PM incubated with LPBS, LDMDP, and
DMDP for 24 and 48 ha
|
|
In vitro effects of LPBS, LDMDP, and DMDP on the morphology and
phagocytic capacity of murine AM.
These experiments were repeated
three times, and the trend was identical for all. Due to large
day-to-day biological variability, one representative experiment is
shown (Fig. 2). In it, 100% of untreated
(control) and LPBS-treated macrophages appeared to be healthy, whereas
61, 88, and 61% of AM showed unhealthy characteristics after
incubation with LDMDP for 24, 48, and 72 h, respectively. All AM
incubated with free DMDP for 24, 48, and 72 h appeared to be
unhealthy, with no cytoplasm visible.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 2.
Effects of LPBS, LDMDP, and DMDP on murine AM in vitro.
AM, plated on coverslips, were incubated with 15 µl of LPBS, LDMDP,
or DMDP (0.6 M stock) for 24 h (A), 48 h (B), and 72 h
(C). Controls received no treatment. The morphology of the treated AM
was assessed microscopically. One hundred macrophages per coverslip
were scored. The experiments were repeated at least three times. The
percentages of healthy macrophages ( ) and unhealthy macrophages
( ) were compared. Results of one representative experiment are
shown.
|
|
LPBS-treated AM ingested numbers of
P. aeruginosa
organisms similar to those ingested by untreated cells, whereas
LDMDP- and
DMDP-treated AM ingested negligible numbers of bacteria.
The percentage
of LDMDP- and DMDP-treated AM that ingested bacteria was
substantially
lower than that of control and LPBS-treated AM. AM
incubated with
DMDP had no visible cytoplasm; therefore, the ingestion
of
P. aeruginosa was not observed (data not
shown).
In vitro effects of LPBS, LDMDP, and DMDP on respiratory epithelial
cell line A549.
Changes in the morphology of the respiratory
epithelial cell line were not observed after 24 and 48 h of
incubation with LPBS or LDMDP. However, unincorporated DMDP was toxic.
At 48 h, the percentage of A549 cells with unhealthy
characteristics
shriveled nuclei and cytoplasm
increased with
increasing concentrations of DMDP (8 to 15% of cells incubated with
0.5 or 5 mM DMDP, 23 to 33% of cells incubated with 50 mM DMDP, and 80 to 85% of A549 cells incubated with 0.6 M DMDP).
In vivo depletion of AM by i.n. instillation of LDMDP.
Figure
3 shows that 24 and 48 h after the
i.n. instillation of 50 µl of LPBS or LDMDP, the number of AM
recovered from LDMDP-treated mice was substantially lower than that
recovered from LPBS-treated mice. At 72 h, the number of AM in the
BAL from the LDMDP-treated group was slightly increased (data not
shown). The histologic appearance of the lungs from LPBS- and
LDMDP-treated mice was similar (data not shown).

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 3.
Depletion of AM in vivo by i.n. instillation of DMDP.
Fifty microliters of LPBS or LDMDP was delivered to mice by i.n.
instillation; 24 and 48 h after the instillation of liposomes, BAL
was performed and the number of AM in the BAL fluid was determined from
hemocytometer counts and cytocentrifuged preparations. The number of AM
in BAL fluid from LPBS-treated ( ) and LDMDP-treated ( ) mice at 24 and 48 h postinstillation is shown. Experiments were repeated
three times. Data are expressed as means plus SEM.
|
|
Effects of AM depletion on P. aeruginosa clearance in
vivo.
There was no difference between AM-depleted and nondepleted
BALB/c and CD-1 mice infected with P. aeruginosa in the
clearance of viable bacteria (Fig. 4A
through C). No viable bacteria were isolated from the spleens or livers
of the infected mice at these time points (data not shown). The number
of PMNs isolated from AM-depleted mice was not substantially different
from that obtained from nondepleted mice for 5 days postinfection (data
not shown). A histologic examination of the lungs of AM-depleted and
control infected mice revealed increased numbers of PMNs compared to
those of AM-depleted and control uninfected mice (data not shown).
Cytospin preparations of BAL cells from LPBS- and LDMDP-treated mice
showed that recruited PMNs were competent to phagocytose P. aeruginosa. However, AM appeared not to have phagocytosed the
bacteria (Fig. 5). Further studies with
LPBS- and LDMDP-treated mice challenged i.n. with P. aeruginosa strain PA01 at various doses
1.32 × 107, 6.5 × 105, and 9 × 103 CFU
did not show any difference between the two groups
of mice in bacterial clearance (data not shown).

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 4.
Effects of AM depletion in BALB/c and CD-1 mice on
P. aeruginosa and K. pneumoniae clearance in
vivo. BALB/c mice, 24 h after the i.n. instillation of LPBS ( )
or LDMDP ( ), were challenged i.n. with P. aeruginosa FRD1
(6.0 × 106 CFU) (A) and PA01 (2.7 × 107 CFU) (B). CD-1 mice were challenged with PA01 (6.9 × 106 CFU) (C), and BALB/c mice were challenged with
K. pneumoniae (1.0 × 102 CFU) (D).
Depletion of AM was confirmed by BAL counts and cytospin preparations
on the day of infection. At 3 h (day 0), 24 h (day 1),
48 h (day 2), and 120 h (day 5) postinfection, bacterial
counts in lung homogenates were determined. Data are expressed as
means ± SEM of CFU (log10) per gram of lung tissue
from three mice at each time point. , mice were euthanized due to
signs of disease.
|
|

View larger version (92K):
[in this window]
[in a new window]
|
FIG. 5.
Differential determination of leukocytes from BAL
performed on P. aeruginosa-challenged mice pretreated with
LPBS or LDMDP. BAL differentials were calculated for LPBS-treated mice
(A) and LDMDP-treated mice (B) 3 h after their i.n. inoculation
with P. aeruginosa strain PA01 (6.9 × 106
CFU). Magnification, ×1,125. Arrowheads indicate bacteria within
PMN.
|
|
Effects of AM depletion on K. pneumoniae clearance in
vivo.
Figure 4D shows a striking difference between AM-depleted
and nondepleted BALB/c mice in the number of viable bacteria. Signs of
disease were evident 48 h after the i.n. instillation of K. pneumoniae (100 CFU/mouse) in the LDMDP-depleted mice, while
LPBS-treated mice appeared to be healthy. The spleens and livers of
LDMDP-treated mice harbored high numbers of K. pneumoniae
cells, but the same tissues from control animals were sterile.
In vitro phagocytosis of freshly explanted AM.
Unopsonized
P. aeruginosa was poorly ingested by freshly explanted
murine AM from BALB/c and CD-1 mice in the presence or absence of
D-glucose. Freshly explanted murine resident PM ingested unopsonized P. aeruginosa strain P1 only in the presence of
D-glucose but ingested strain PAK with or without glucose.
AM and PM phagocytosed similar numbers of zymosan particles (data not shown).
In situ phagocytic activities of AM.
In untreated and
uninfected control mice, mononuclear cells comprised 99 to 100% of BAL
cells and PMNs comprised less than 1% (Fig.
6A). Recruitment of neutrophils to the
lung was substantially enhanced after infection with high doses of
P. aeruginosa
PAK at 108 CFU and P1, c2908c,
and FRD1 at 107 CFU. PMN recruitment to the lung was
minimal in mice inoculated with zymosan particles and latex beads.
Figure 6B shows the percentage of AM and PMNs with ingested particles
in the BAL population. AM phagocytosis of P. aeruginosa (0 to 5%) was much lower than that of zymosan particles (23%) and latex
beads (27%).

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 6.
In situ phagocytic activities of AM. Three hours after
the i.n. instillation of P. aeruginosa, zymosan particles,
or latex beads, BAL was performed. Differential counts were performed
on cytospin preparations, and the percentage of neutrophils was
assessed. Each sample was performed in triplicate. One hundred BAL
cells were counted. Results are expressed as means plus SEM. (A)
Percentages of AM and PMNs in the BAL cell population; (B) percentages
of AM and PMNs with ingested particles in the BAL cell population.
|
|
 |
DISCUSSION |
AM depletion did not compromise the capacity of BALB/c or CD-1
mice to clear P. aeruginosa from the lung. However, AM
depletion was noted by others to profoundly compromise pulmonary host
defenses against P. aeruginosa and other respiratory
pathogens (4, 15, 16). AM depletion results in reduced
killing of Mycoplasma pulmonis in C57BL/6 mice
(15). Forty-eight hours after K. pneumoniae inoculation, mice with 65% AM depletion show increased bacterial counts in lungs compared to control infected mice (4).
However, K. pneumoniae is more virulent than P. aeruginosa; 100 CFU of the former was used to infect mice
(4), whereas a much higher dose (106 CFU) of
P. aeruginosa can be cleared from the lungs of normal mice.
The discrepancy between our results with P. aeruginosa-infected AM-depleted mice and those with
Klebsiella (4) and M. pulmonis (15) may be due to differences in infecting agents. This
difference was confirmed by the experiments that we performed with
K. pneumoniae. On the other hand, decreased bacterial
clearance has been observed in CD-1 mice depleted of AM and infected
with P. aeruginosa (16). The discrepancy between
our results and those of Kooguchi et al. (16) may be due to
the method of LDMDP administration, the infecting dose of bacteria, and
the strain of P. aeruginosa used. Liposomes can be disrupted
by nebulization (9), thereby releasing their contents into
the endobronchial space. We chose to deliver LDMDP by i.n. inoculation
to avoid the potentially toxic effects of free DMDP. The enhanced
susceptibility of LDMDP-treated mice to pulmonary P. aeruginosa infection observed by Kooguchi et al. (16)
may have resulted from the nonspecific effect of DMDP on multiple
components of the respiratory tract. Our i.n. instillation likely
conserved the integrity of the liposomes and delivered them
specifically to AM with subsequent selective depletion. This effect was
supported by our studies with K. pneumoniae.
Previous in vitro studies have shown that AM actively phagocytose
liposomes; AM display the morphological traits characteristic of
ongoing phagocytic activity, such as grossly irregular perimeters and
extensive pseudopod formation (20). The effects of LDMDP on
the phagocytic competence of PM and AM were more apparent than those
exerted by LPBS, suggesting that a significant decrease in the
phagocytosis of P. aeruginosa by macrophages was not due to
liposomes alone. The results of these in vitro experiments assessing
the effects of LPBS, LDMDP, and DMDP on AM and PM correlated with those
of an in vitro study of rat AM incubated with LPBS, LDMDP, and DMDP
(2). LDMDP-treated AM and PM had shriveled nuclei and
cytoplasm, suggesting that they had undergone apoptosis (4, 18,
27). AM and PM treated with free DMDP were lysed, resulting in a
loss of cytoplasm, indicating that the mechanisms by which DMDP and
LDMDP affect macrophages are not the same. A549 respiratory epithelial
cells incubated with high concentrations of free DMDP showed the same
change in morphology as the macrophages. However, the concentration of
DMDP used in in vitro assays was higher than that incorporated into
LDMDP. During liposomal preparation, only 1% of DMDP is encapsulated
into LDMDP (28). No change in the morphology of epithelial
cells incubated with LPBS and LDMDP was observed, suggesting that these
liposomes administered in vivo in mice would not likely affect the
respiratory epithelium in mice; their effects appear to be limited to macrophages.
Recruitment of PMNs to the lung was not impaired in LDMDP-treated
mice. PMNs did not appear to be affected by LDMDP or LPBS, consistent
with the results of in vitro and in vivo experiments demonstrating that
neutrophils are not affected by LDMDP (4). PMNs, but not AM,
actively phagocytosed P. aeruginosa, as shown in BAL
preparations from both groups of mice, indicating that PMNs actively
participated in bacterial clearance. In the uninfected or untreated
lung, PMNs comprise a small proportion of cells in the lower
respiratory tract and macrophages constitute 85 to 98% of cells
(15, 26, 29). However, the number of PMNs increases in lungs
challenged with P. aeruginosa by intratracheal inoculation (19).
Poor nonopsonic phagocytosis of P. aeruginosa by freshly
explanted murine AM correlated well with previously published data on
freshly explanted and cultivated murine AM, where the former, but not
the latter, showed negligible phagocytosis of unopsonized P. aeruginosa (8, 29). However, the ingestion of zymosan particles and latex beads by freshly explanted AM demonstrated that
they were phagocytically competent. The phagocytic activities of
freshly explanted AM from BALB/c and CD-1 mice were similar, suggesting
that the poor phagocytic capacity of uncultivated AM is not mouse
strain specific. The difference in phagocytic competency between
freshly explanted AM and PM may be due to their differential glycolytic
activities. AM reside in the oxygen-rich environment of lung airways
(13% O2), whereas PM are in the relatively anaerobic peritoneum (6.5% O2); therefore, their metabolic capacity
and dependence upon oxidative phosphorylation versus glycolysis are quite dissimilar, as would be their capacity to transport glucose and
to ingest bacteria in a glucose-dependent fashion (6, 8, 22). The association of glucose transport and nonopsonic
phagocytosis of P. aeruginosa has been previously reported
(1, 8, 29). In addition to the implicated role of
glycolysis, signal transduction also plays a role in macrophage
phagocytic activities (10, 11). Taken together, the
differences in AM and PM phagocytic competency may be due to their
differential abilities to transport and utilize glucose and initiate
the signalling pathways.
In situ results indicated that AM were phagocytically competent for
control particles but were unable to ingest unopsonized P. aeruginosa, consistent with data from in vitro assays showing poor
nonopsonic phagocytosis by freshly explanted AM. Buret et al.
(5) have demonstrated that the phagocytosis of P. aeruginosa by AM in rats infected with P. aeruginosa
decreases substantially at 4 h postinfection from that at 30 min
after infection, despite an increase in AM numbers. However, the number
of PMNs increases dramatically at 4 h postinfection from that at
30 min postinfection (5). The decreased phagocytic activity
of AM in rats at 4 h postinfection reported by Buret et al. may be
due to the recruitment of other immune cells, such as PMNs, which
migrate to the infected sites and are involved in bacterial clearance,
or to suppression by gamma interferon (23). Bactericidal
activity is higher in neutrophils than in unactivated macrophages, due
to the robust capacity of the former to produce reactive oxygen
radicals (7). The number of PMNs elicited in response to
latex bead and zymosan challenge was minimal. These results suggest
that the recruitment of PMNs is specific and correlates with an
orchestrated response.
In summary, depletion of the majority of AM in mice did not result in
decreased clearance of P. aeruginosa or impairment of PMN
recruitment. AM were phagocytically competent but inefficient in
ingesting unopsonized P. aeruginosa in vitro and in situ,
whereas PMNs recruited upon bacterial challenge phagocytosed
unopsonized P. aeruginosa. These results suggest that the
role of AM in defense of the lung against P. aeruginosa
challenge may rely upon their capacity to recruit other phagocytic
cells rather than on their intrinsic phagocytic function.
 |
ACKNOWLEDGMENTS |
This project was supported by a studentship (to D.O.Y.C.) and
operating grants (to D.P.S.) from the Canadian Cystic Fibrosis Foundation and the Medical Research Council of Canada.
We thank Robert E. W. Hancock for assistance in liposomal preparations.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Room 377, Research Centre, 950 West 28th Ave., Vancouver, BC, V5Z 4H4,
Canada. Phone: (604) 875-2438. Fax: (604) 875-2226. E-mail:
speert{at}interchange.ubc.ca.
Editor:
E. I. Tuomanen
 |
REFERENCES |
| 1.
|
Barghouthi, S.,
K. D. E. Everett, and D. P. Speert.
1995.
Nonopsonic phagocytosis of Pseudomonas aeruginosa requires facilitated transport of D-glucose by macrophages.
J. Immunol.
154:3420-3428[Abstract].
|
| 2.
|
Berg, J. T.,
S. T. Lee,
T. Thepen,
C. Y. Lee, and M. F. Tsan.
1993.
Depletion of alveolar macrophages by liposome-encapsulated dichloromethylene diphosphonate.
J. Appl. Physiol.
74:2812-2819[Abstract/Free Full Text].
|
| 3.
|
Berger, M.,
T. M. Norvell,
M. F. Tosi,
S. N. Emancipator,
M. W. Konstan, and J. R. Schreiber.
1994.
Tissue-specific Fc and complement receptor expression by alveolar macrophages determines relative importance of IgG and complement in promoting phagocytosis of Pseudomonas aeruginosa.
Pediatr. Res.
35:68-77[Medline].
|
| 4.
|
Broug-Holub, E.,
G. B. Toews,
J. F. Van Iwaarden,
R. M. Strieter,
S. L. Kunkel,
R. Paine III, and T. J. Standiford.
1997.
Alveolar macrophages are required for protective pulmonary defenses in murine Klebsiella pneumonia: elimination of alveolar macrophages increases neutrophil recruitment but decreases bacterial clearance and survival.
Infect. Immun.
65:1139-1146[Abstract].
|
| 5.
|
Buret, A.,
M. L. Dunkley,
G. Pang,
R. L. Clancy, and A. W. Cripps.
1994.
Pulmonary immunity to Pseudomonas aeruginosa in intestinally immunized rats: roles of alveolar macrophages, tumor necrosis factor alpha, and interleukin-1 .
Infect. Immun.
62:5335-5343[Abstract/Free Full Text].
|
| 6.
|
Butterick, C. J.,
D. A. Williams,
L. A. Boxer,
R. A. Jersild, Jr.,
N. Mantich,
C. Higgins, and R. L. Baehner.
1981.
Changes in energy metabolism, structure and function in alveolar macrophages under anaerobic conditions.
Br. J. Haematol.
48:523-532[Medline].
|
| 7.
|
Campa, M.,
M. Bendinelli, and H. Friedman.
1993.
Pseudomonas aeruginosa as an opportunistic pathogen.
Plenum Press, New York, N.Y.
|
| 8.
|
Everett, K. D. E.,
S. Barghouthi, and D. P. Speert.
1996.
In vitro culture of murine peritoneal and alveolar macrophages modulates phagocytosis of Pseudomonas aeruginosa and glucose transport.
J. Leukoc. Biol.
59:539-544[Abstract].
|
| 9.
|
Finlay, W. H., and J. P. Wong.
1998.
Regional lung deposition of nebulized liposome-encapsulated ciprofloxacin.
Int. J. Pharm.
167:121-127[CrossRef].
|
| 10.
|
Goodall, G. J.,
C. J. Bagley,
M. A. Vadas, and A. F. Lopez.
1993.
A model for the interaction of the GM-CSF, IL-3 and IL-5 receptors with their ligands.
Growth Factors
8:87-97[Medline].
|
| 11.
|
Greenberg, S.
1995.
Signal transduction of phagocytosis.
Trends Cell Biol.
5:93-99[CrossRef][Medline].
|
| 12.
|
Hancock, R. E. W., and D. P. Speert.
1996.
Antibiotics for Pseudomonas and related infections, p. 245-266.
In
J. A. Dodge, D. J. H. Brock, and J. H. Widdicombe (ed.), Cystic fibrosis current topics, vol. 3. John Wiley and Sons, Toronto, Canada.
|
| 13.
|
Hashimoto, S.,
J. F. Pittet,
K. Hong,
H. Folkesson,
G. Bagby,
L. Kobzik,
C. Frevert,
K. Watanabe,
S. Tsurufujia, and J. Wiener-Kronish.
1996.
Depletion of alveolar macrophages decreases neutrophil chemotaxis to Pseudomonas airspace infections.
Am. J. Physiol.
270:L819-L824[Abstract/Free Full Text].
|
| 14.
|
Hauschildt, S., and B. Kleine.
1995.
Bacterial stimulators of macrophages.
Int. Rev. Cytol.
161:263-331[Medline].
|
| 15.
|
Hickman-Davis, J. M.,
S. M. Michalek,
J. Gibbs-Erwin, and J. R. Lindsey.
1997.
Depletion of alveolar macrophages exacerbates respiratory mycoplasmosis in mycoplasma-resistant C57BL mice but not mycoplasma-susceptible C3H mice.
Infect. Immun.
65:2278-2282[Abstract].
|
| 16.
|
Kooguchi, K.,
S. Hashimoto,
A. Kobayashi,
Y. Kitamura,
I. Kudoh,
J. Wiener-Kronish, and T. Sawa.
1998.
Role of alveolar macrophages in initiation and regulation of inflammation in Pseudomonas aeruginosa pneumonia.
Infect. Immun.
66:3164-3169[Abstract/Free Full Text].
|
| 17.
|
Limper, A. H.,
J. S. Hoyte, and J. E. Standing.
1997.
The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung.
J. Clin. Investig.
99:2110-2117[Medline].
|
| 18.
|
Naito, M.,
H. Nagai,
S. Kawano,
H. Umezu,
H. Zhu,
H. Moriyama,
T. Yamamoto,
H. Takatsuka, and Y. Takei.
1996.
Liposome-encapsulated dichloromethylene diphosphonate induces macrophage apoptosis in vivo and in vitro.
J. Leukoc. Biol.
60:337-344[Abstract].
|
| 19.
|
Ozaki, R.,
M. Maeda,
H. Hayashi,
Y. Nakamura,
H. Moriguchi,
T. Kamei,
S. Yasuoka, and T. Ogura.
1989.
Role of alveolar macrophages in the neutrophil-dependent defense system against Pseudomonas aeruginosa infection in the lower respiratory tract.
Am. Rev. Respir. Dis.
140:1595-1601[Medline].
|
| 20.
|
Perry, D. G., and W. J. Martin, II.
1995.
Fluorescent liposomes as quantitative markers of phagocytosis by alveolar macrophages.
J. Immunol. Methods
181:269-285[CrossRef][Medline].
|
| 21.
|
Speert, D. P.
1994.
Pseudomonas aeruginosa infections in patients with cystic fibrosis, p. 183-236.
In
A. L. Baltch, and R. P. Smith (ed.), Pseudomonas aeruginosa: infections and treatment. Marcel Dekker, Inc., New York, N.Y.
|
| 22.
|
Speert, D. P., and S. Gordon.
1992.
Phagocytosis of unopsonized Pseudomonas aeruginosa by murine macrophages is a two-step process requiring glucose.
J. Clin. Investig.
90:1085-1095.
|
| 23.
|
Speert, D. P., and L. Thorson.
1991.
Suppression by human recombinant gamma interferon of in vitro macrophage nonopsonic and opsonic phagocytosis and killing.
Infect. Immun.
59:1893-1898[Abstract/Free Full Text].
|
| 24.
|
Stokes, R. W.,
L. M. Thorson, and D. P. Speert.
1998.
Nonopsonic and opsonic association of Mycobacterium tuberculosis with resident alveolar macrophages is inefficient.
J. Immunol.
160:5514-5521[Abstract/Free Full Text].
|
| 25.
|
Tang, H.,
M. Kays, and A. Prince.
1995.
Role of Pseudomonas aeruginosa pili in acute pulmonary infection.
Infect. Immun.
63:1278-1285[Abstract].
|
| 26.
|
Tsuji, C.,
M. U. Minhaz,
S. Shioya,
M. Fukahori,
T. Tanigaki, and H. Nakazawa.
1998.
The importance of polymorphonuclear leukocytes in lipopolysaccharide-induced superoxide anion production and lung injury: ex vivo observation in rat lungs.
Lung
176:1-13[CrossRef][Medline].
|
| 27.
|
Van Rooijen, N., and A. Sanders.
1997.
Elimination, blocking, and activation of macrophages: three of a kind?
J. Leukoc. Biol.
62:702-709[Abstract].
|
| 28.
|
Van Rooijen, N., and A. Sanders.
1994.
Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications.
J. Immunol. Methods
174:83-93[CrossRef][Medline].
|
| 29.
|
Wong, S. Y. C.,
L. M. Guerdoud,
A. Cantin, and D. P. Speert.
1999.
Glucose stimulates phagocytosis of unopsonized Pseudomonas aeruginosa by cultivated human alveolar macrophages.
Infect. Immun.
67:16-21[Abstract/Free Full Text].
|
Infection and Immunity, August 2000, p. 4585-4592, Vol. 68, No. 8
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Koh, A. Y., Priebe, G. P., Ray, C., Van Rooijen, N., Pier, G. B.
(2009). Inescapable Need for Neutrophils as Mediators of Cellular Innate Immunity to Acute Pseudomonas aeruginosa Pneumonia. Infect. Immun.
77: 5300-5310
[Abstract]
[Full Text]
-
Manicone, A. M., Birkland, T. P., Lin, M., Betsuyaku, T., van Rooijen, N., Lohi, J., Keski-Oja, J., Wang, Y., Skerrett, S. J., Parks, W. C.
(2009). Epilysin (MMP-28) Restrains Early Macrophage Recruitment in Pseudomonas aeruginosa Pneumonia. J. Immunol.
182: 3866-3876
[Abstract]
[Full Text]
-
Kannan, S., Audet, A., Huang, H., Chen, L.-j., Wu, M.
(2008). Cholesterol-Rich Membrane Rafts and Lyn Are Involved in Phagocytosis during Pseudomonas aeruginosa Infection. J. Immunol.
180: 2396-2408
[Abstract]
[Full Text]
-
Fuschillo, S., De Felice, A., Balzano, G.
(2008). Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J
31: 396-406
[Abstract]
[Full Text]
-
Wilson, K. R., Napper, J. M., Denvir, J., Sollars, V. E., Yu, H. D.
(2007). Defect in early lung defence against Pseudomonas aeruginosa in DBA/2 mice is associated with acute inflammatory lung injury and reduced bactericidal activity in naive macrophages. Microbiology
153: 968-979
[Abstract]
[Full Text]
-
Shea, J. M., Kechichian, T. B., Luberto, C., Del Poeta, M.
(2006). The cryptococcal enzyme inositol phosphosphingolipid-phospholipase C confers resistance to the antifungal effects of macrophages and promotes fungal dissemination to the central nervous system.. Infect. Immun.
74: 5977-5988
[Abstract]
[Full Text]
-
Lu, W., Hisatsune, A., Koga, T., Kato, K., Kuwahara, I., Lillehoj, E. P., Chen, W., Cross, A. S., Gendler, S. J., Gewirtz, A. T., Kim, K. C.
(2006). Cutting Edge: Enhanced Pulmonary Clearance of Pseudomonas aeruginosa by Muc1 Knockout Mice. J. Immunol.
176: 3890-3894
[Abstract]
[Full Text]
-
Hajjar, A. M., Harowicz, H., Liggitt, H. D., Fink, P. J., Wilson, C. B., Skerrett, S. J.
(2005). An Essential Role for Non-Bone Marrow-Derived Cells in Control of Pseudomonas aeruginosa Pneumonia. Am. J. Respir. Cell Mol. Bio.
33: 470-475
[Abstract]
[Full Text]
-
Shao, X., Mednick, A., Alvarez, M., van Rooijen, N., Casadevall, A., Goldman, D. L.
(2005). An Innate Immune System Cell Is a Major Determinant of Species-Related Susceptibility Differences to Fungal Pneumonia. J. Immunol.
175: 3244-3251
[Abstract]
[Full Text]
-
Worgall, S., Heguy, A., Luettich, K., O'Connor, T. P., Harvey, B.-G., Quadri, L. E. N., Crystal, R. G.
(2005). Similarity of Gene Expression Patterns in Human Alveolar Macrophages in Response to Pseudomonas aeruginosa and Burkholderia cepacia. Infect. Immun.
73: 5262-5268
[Abstract]
[Full Text]
-
Ader, F., Le Berre, R., Faure, K., Gosset, P., Epaulard, O., Toussaint, B., Polack, B., Nowak, E., Viget, N. B., Kipnis, E., Guery, B. P.
(2005). Alveolar Response to Pseudomonas aeruginosa: Role of the Type III Secretion System. Infect. Immun.
73: 4263-4271
[Abstract]
[Full Text]
-
Sadikot, R. T., Blackwell, T. S., Christman, J. W., Prince, A. S.
(2005). Pathogen-Host Interactions in Pseudomonas aeruginosa Pneumonia. Am. J. Respir. Crit. Care Med.
171: 1209-1223
[Abstract]
[Full Text]
-
Drannik, A. G., Pouladi, M. A., Robbins, C. S., Goncharova, S. I., Kianpour, S., Stampfli, M. R.
(2004). Impact of Cigarette Smoke on Clearance and Inflammation after Pseudomonas aeruginosa Infection. Am. J. Respir. Crit. Care Med.
170: 1164-1171
[Abstract]
[Full Text]
-
Chu, K. K., MacDonald, K. L., Davidson, D. J., Speert, D. P.
(2004). Persistence of Burkholderia multivorans within the Pulmonary Macrophage in the Murine Lung. Infect. Immun.
72: 6142-6147
[Abstract]
[Full Text]
-
Dockrell, D. H., Marriott, H. M., Prince, L. R., Ridger, V. C., Ince, P. G., Hellewell, P. G., Whyte, M. K. B.
(2003). Alveolar Macrophage Apoptosis Contributes to Pneumococcal Clearance in a Resolving Model of Pulmonary Infection. J. Immunol.
171: 5380-5388
[Abstract]
[Full Text]
-
Knapp, S., Leemans, J. C., Florquin, S., Branger, J., Maris, N. A., Pater, J., van Rooijen, N., van der Poll, T.
(2003). Alveolar Macrophages Have a Protective Antiinflammatory Role during Murine Pneumococcal Pneumonia. Am. J. Respir. Crit. Care Med.
167: 171-179
[Abstract]
[Full Text]
-
Lin, T.-J., Garduno, R., Boudreau, R. T. M., Issekutz, A. C.
(2002). Pseudomonas aeruginosa Activates Human Mast Cells to Induce Neutrophil Transendothelial Migration Via Mast Cell-Derived IL-1{alpha} and {beta}. J. Immunol.
169: 4522-4530
[Abstract]
[Full Text]
-
Koay, M. A., Gao, X., Washington, M. K., Parman, K. S., Sadikot, R. T., Blackwell, T. S., Christman, J. W.
(2002). Macrophages Are Necessary for Maximal Nuclear Factor-kappa B Activation in Response to Endotoxin. Am. J. Respir. Cell Mol. Bio.
26: 572-578
[Abstract]
[Full Text]
-
Santosuosso, M., Divangahi, M., Zganiacz, A., Xing, Z.
(2002). Reduced tissue macrophage population in the lung by anticancer agent cyclophosphamide: restoration by local granulocyte macrophage-colony-stimulating factor gene transfer. Blood
99: 1246-1252
[Abstract]
[Full Text]
-
Maus, U. A., Koay, M. A., Delbeck, T., Mack, M., Ermert, M., Ermert, L., Blackwell, T. S., Christman, J. W., Schlondorff, D., Seeger, W., Lohmeyer, J.
(2002). Role of resident alveolar macrophages in leukocyte traffic into the alveolar air space of intact mice. Am. J. Physiol. Lung Cell. Mol. Physiol.
282: L1245-L1252
[Abstract]
[Full Text]